Compare Supplements

Investigational / China-only dosing: once-weekly subcutaneous injection, dose-escalated over several weeks. Trial maintenance doses studied were 4 mg, 6 mg, and 9 mg once weekly (lower doses used during titration to limit GI effects). There is no FDA-approved regimen.

Any time

Once-weekly subcutaneous injection (investigational; China-approved as Xinermei)

Prescription-only, clinician-titrated. Subcutaneous (Wegovy weight management: escalate to 2.4 mg once weekly; Ozempic diabetes: 0.5-2.0 mg once weekly). Oral (Rybelsus diabetes: 3-14 mg once daily). DO NOT self-dose.

Any time

Subcutaneous once-weekly injection (Ozempic / Wegovy)

• Pregnancy and breastfeeding
• Personal or family history of medullary thyroid carcinoma or MEN2 (class-level precaution for GLP-1-based agents)
• History of pancreatitis (use with caution / avoid)

• Insulin and sulfonylureas
• Oral medications generally

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Prior serious hypersensitivity to semaglutide or any GLP-1 receptor agonist

• Insulin and sulfonylureas
• Oral medications (general)
• Other GLP-1 receptor agonists